Patient-Oriented Research in Beryllium-Induced Disease
以患者为导向的铍诱发疾病研究
基本信息
- 批准号:8451406
- 负责人:
- 金额:$ 15.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-04-01 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAlanineAllelesAlveolitisAmino AcidsAntigen-Presenting CellsAntigensAttentionAwardBerylliosisBerylliumBindingBinding SitesBiologicalBiological MarkersBloodBronchoalveolar LavageCD4 Positive T LymphocytesCDR1 geneChronic berylliosisClinical SciencesClonal ExpansionCollaborationsColoradoComplementComplementarity Determining RegionsComplexDataDengueDengue VirusDevelopmentDiseaseDisease ProgressionDisease susceptibilityDissectionEducational process of instructingEnsureEpitopesFacultyFibroblastsFrequenciesFunctional disorderFundingGenetic Predisposition to DiseaseGlutamic AcidGoalsGranulomatousHLA-DP AntigensHLA-DP2HealthHumanHybridomasImmuneImmune responseImmunologyIndustryInflammationInstitutesInterferonsInterleukin-2LeadLigandsLinkLungLung diseasesMediatingMentored Clinical Scientist Development ProgramMentorsMetalsMethionineModalityModelingMusMutateMutationOccupationalOrganPatientsPeptide LibraryPeptidesPhysiciansPlayPopulationPositioning AttributePulmonologyQuality of lifeResearchResearch InfrastructureResearch SupportResearch TrainingResourcesRestRoleScientistSeverity of illnessSite-Directed MutagenesisSocial WelfareSpecimenStaining methodStainsStructureSurface AntigensT memory cellT-Cell ActivationT-LymphocyteTNF geneTechnologyTherapeuticTimeTrainingTranslatingTranslational ResearchUniversitiesVertebral columnViralWorkplacebasecarboxylatecareercareer developmentcell typechemical propertycytokinedisorder riskelectron donorfollower of religion Jewishhigh riskhuman subjectimprovedmemory CD4 T lymphocytenext generationpatient oriented researchpatient populationphysical propertyprogramstooltranslational study
项目摘要
DESCRIPTION (provided by applicant): The overall goal of this proposed mid-career award is to enhance Dr. Fontenot's ability to train, mentor and support the career development of fellows, junior faculty and other trainees in patient-oriented research in granulomatous lung disease, in particular beryllium-induced disease. This proposal will insure that Dr. Fontenot has adequate protected time to provide more opportunities for teaching and mentoring fellows, junior faculty and other trainees. In addition, this protected time will allow Dr. Fontenot to participate in coursework that will enhance his ability translate his findings toward improving the quality of life of subjects with beryllium-induced disease. Chronic beryllium disease (CBD) is an occupational lung disease that is characterized by granulomatous inflammation and a CD4+ T cell alveolitis. Due to its unique chemical and physical properties, beryllium continues to be utilized in high-technology industries, with more than 1,000,000 US workers having been exposed to beryllium and at risk for disease development. With the presence of a known antigen and an accessible target organ, CBD is an important model of immune-mediated, organ destruction. We and others have shown the importance of HLA-DP2 in the genetic susceptibility of CBD and in the presentation of beryllium to pathogenic CD4+ T cells. Using blood and bronchoalveolar lavage from human subjects, the goals of the research plan are to elucidate the mechanism by which beryllium-specific CD4+ T cells recognize beryllium in the context of HLA-DP2 and to demonstrate the stability of the beryllium-specific memory T cell pool. Findings from these studies may identify potential biomarkers of disease progression in high-risk subjects as well as therapeutic modalities that block beryllium binding to HLA-DP2 molecules on the surface of antigen presenting cells. This program builds on Dr. Fontenot's recently renewed R01 investigating the role of pathogenic T cells in beryllium-induced disease. The mentoring plan will expand Dr. Fontenot's role in mentoring physician-scientists and other trainees in patient-oriented research. In addition, the research and mentoring plan will leverage the resources and infrastructure present at the University of Colorado and National Jewish Health, including the Clinical Science Program and K12 Program in the Colorado Clinical and Translational Sciences Institute, an outstanding Pulmonary Division with a long track record for successfully training physician-scientists, and long-standing collaborations that bridge basic immunology and patient oriented research, to improve the quality of life of CBD patients. With the support of this award, Dr. Fontenot will become a leader in translational lung immunology research and train the next generation of physician scientists in pulmonary medicine.
描述(由申请人提供):这项拟议的职业中期奖励的总体目标是增强Fontenot博士在以患者为导向的肺部肉芽肿性疾病(特别是铍引起的疾病)研究方面培训、指导和支持研究员、初级教员和其他受训人员的职业发展的能力。这项建议将确保丰特诺博士有足够的保护时间,为教授和指导研究员、初级教员和其他实习生提供更多机会。此外,这段受保护的时间将允许丰特诺博士参加课程作业,这将增强他将自己的发现转化为改善铍诱发疾病受试者的生活质量的能力。慢性铍病(CBD)是一种以肉芽肿性炎症和CD4+T细胞肺泡炎为特征的职业性肺部疾病。由于其独特的化学和物理特性,铍继续被用于高科技行业,有100多万美国工人接触到铍并面临疾病发展的风险。由于存在已知的抗原和可接近的靶器官,CBD是一种重要的免疫介导的器官破坏模型。我们和其他人已经证明了人类白细胞抗原DP2在CBD的遗传易感性和铍对致病的CD4+T细胞的呈递中的重要性。利用人体血液和支气管肺泡灌洗,该研究计划的目标是阐明铍特异性CD4+T细胞在人类白细胞抗原DP2背景下识别铍的机制,并证明铍特异性记忆T细胞池的稳定性。这些研究的结果可能会确定高危受试者疾病进展的潜在生物标记物,以及阻止铍与抗原呈递细胞表面的HLA-DP2分子结合的治疗方法。这个项目建立在Fontenot博士最近更新的R01基础上,该R01研究了致病T细胞在铍诱导的疾病中的作用。该指导计划将扩大丰特诺博士在指导内科科学家和其他以患者为中心的研究实习生方面的作用。此外,研究和指导计划将利用科罗拉多大学和国家犹太健康中心现有的资源和基础设施,包括科罗拉多临床和翻译科学研究所的临床科学计划和K12计划,科罗拉多临床和翻译科学研究所是一个出色的肺科部门,在成功培训医生-科学家方面有着长期的记录,以及连接基础免疫学和以患者为中心的研究的长期合作,以提高CBD患者的生活质量。在这一奖项的支持下,丰特诺博士将成为肺免疫学翻译研究的领导者,并培养下一代肺部医学的内科科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Andrew P. Fontenot其他文献
Hypoxemia Explained 36 Years Later
- DOI:
10.1378/chest.120.5.1739 - 发表时间:
2001-11-01 - 期刊:
- 影响因子:
- 作者:
Brian W. Fouty;David A. Lynch;Andrew P. Fontenot;Marvin I. Schwarz - 通讯作者:
Marvin I. Schwarz
Correction to: An exploration of Prevotella-rich microbiomes in HIV and men who have sex with men
- DOI:
10.1186/s40168-020-00829-6 - 发表时间:
2020-04-06 - 期刊:
- 影响因子:12.700
- 作者:
Abigail J. S. Armstrong;Michael Shaffer;Nichole M. Nusbacher;Christine Griesmer;Suzanne Fiorillo;Jennifer M. Schneider;C. Preston Neff;Sam X. Li;Andrew P. Fontenot;Thomas Campbell;Brent E. Palmer;Catherine A. Lozupone - 通讯作者:
Catherine A. Lozupone
Andrew P. Fontenot的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Andrew P. Fontenot', 18)}}的其他基金
Interactions between antigen-specific effector and regulatory T cells in beryllium-induced disease
铍诱发疾病中抗原特异性效应细胞和调节性 T 细胞之间的相互作用
- 批准号:
9040746 - 财政年份:2016
- 资助金额:
$ 15.29万 - 项目类别:
Interactions between antigen-specific effector and regulatory T cells in beryllium-induced disease
铍诱发疾病中抗原特异性效应细胞和调节性 T 细胞之间的相互作用
- 批准号:
9198986 - 财政年份:2016
- 资助金额:
$ 15.29万 - 项目类别:
Project 3 - T Cells in Beryllium Sensitization and Disease
项目 3 - 铍致敏和疾病中的 T 细胞
- 批准号:
8382599 - 财政年份:2012
- 资助金额:
$ 15.29万 - 项目类别:
Development of an HLA-DP2 Transgenic Murine Model of Chronic Beryllium Disease
慢性铍病 HLA-DP2 转基因小鼠模型的建立
- 批准号:
8223751 - 财政年份:2012
- 资助金额:
$ 15.29万 - 项目类别:
Development of an HLA-DP2 Transgenic Murine Model of Chronic Beryllium Disease
慢性铍病 HLA-DP2 转基因小鼠模型的建立
- 批准号:
8389617 - 财政年份:2012
- 资助金额:
$ 15.29万 - 项目类别:
Patient-Oriented Research in Beryllium-Induced Disease
以患者为导向的铍诱发疾病研究
- 批准号:
8649067 - 财政年份:2010
- 资助金额:
$ 15.29万 - 项目类别:
Patient-Oriented Research in Beryllium-Induced Disease
以患者为导向的铍诱发疾病研究
- 批准号:
8055025 - 财政年份:2010
- 资助金额:
$ 15.29万 - 项目类别:
Patient-Oriented Research in Beryllium-Induced Disease
以患者为导向的铍诱发疾病研究
- 批准号:
8242725 - 财政年份:2010
- 资助金额:
$ 15.29万 - 项目类别:
Patient-Oriented Research in Beryllium-Induced Disease
以患者为导向的铍诱发疾病研究
- 批准号:
7869189 - 财政年份:2010
- 资助金额:
$ 15.29万 - 项目类别:
相似海外基金
Biosynthesis of bet-alanine in autolysosomes.
自溶酶体中 β-丙氨酸的生物合成。
- 批准号:
22K08681 - 财政年份:2022
- 资助金额:
$ 15.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding the metabolic consequences of the systemic alanine depletion in pancreatic ductal adenocarcinoma
了解胰腺导管腺癌中全身丙氨酸消耗的代谢后果
- 批准号:
474506 - 财政年份:2022
- 资助金额:
$ 15.29万 - 项目类别:
Studentship Programs
Characterizing alanine transporters as therapeutic targets for pancreatic cancer
将丙氨酸转运蛋白描述为胰腺癌的治疗靶点
- 批准号:
466496 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
Studentship Programs
Understanding the requirements of alanine supply and demand in pancreatic ductal adenocarcinoma
了解胰腺导管腺癌中丙氨酸的供需要求
- 批准号:
451838 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
Operating Grants
Sensing living P. aeruginosa using D-alanine derived radiotracers
使用 D-丙氨酸衍生的放射性示踪剂感测活的铜绿假单胞菌
- 批准号:
10230924 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
Sensing living P. aeruginosa using D-alanine derived radiotracers
使用 D-丙氨酸衍生的放射性示踪剂感测活的铜绿假单胞菌
- 批准号:
10399593 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
Sensing living P. aeruginosa using D-alanine derived radiotracers
使用 D-丙氨酸衍生的放射性示踪剂感测活的铜绿假单胞菌
- 批准号:
10570987 - 财政年份:2021
- 资助金额:
$ 15.29万 - 项目类别:
Spot measurement of alanine radicals produced by irradiation and application of sugar radial to dosimeter
辐照产生的丙氨酸自由基的点测及糖自由基在剂量计中的应用
- 批准号:
19K05343 - 财政年份:2019
- 资助金额:
$ 15.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Metabolic significance of lysosomal beta-alanine
溶酶体β-丙氨酸的代谢意义
- 批准号:
18K08528 - 财政年份:2018
- 资助金额:
$ 15.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Development of dosimetry technique for IMRT using alanine dosimeter
使用丙氨酸剂量计开发 IMRT 剂量测定技术
- 批准号:
18K15615 - 财政年份:2018
- 资助金额:
$ 15.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists